Association between essential hypertension and three vasoactive peptides, urotensin II, endothelin and adrenomedullin

References

• Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57:450–8
   PubMed Web of Science ®Google Scholar
• González J, Valls N, Brito R, Rodrigo R. Essential hypertension and oxidative stress: new insights. World J Cardiol 2014;6:353
   PubMedGoogle Scholar
• Peng H, Zhang M, Cai X, et al. Association between human urotensin II and essential hypertension—a 1: 1 matched case-control study. PLoS One 2013;8:e81764
   PubMed Web of Science ®Google Scholar
• Gómez-Guzmán M, Jiménez R, Sánchez M, et al. Epicatechin lowers blood pressure, restores endothelial function, and decreases oxidative stress and endothelin-1 and NADPH oxidase activity in DOCA-salt hypertension. Free Radic Biol Med 2012;52:70–9
   PubMed Web of Science ®Google Scholar
• Rautureau Y, Schiffrin EL. Endothelin in hypertension: an update. Curr Opin Nephrol Hypertens 2012;21:128–36
   PubMed Web of Science ®Google Scholar
• Kong D-G, Gao H, Lu Y-Q, et al. Anxiety disorders are associated with increased plasma adrenomedullin level and left ventricular hypertrophy in patients with hypertension. Clin Exp Hypertens 2013;36:27–31
   PubMed Web of Science ®Google Scholar
• Kato J, Kuwasako K, Kitamura K. Adrenomedullin in hypertension and obesity. Curr Hypertens Rev 2011;7:257–67
   Google Scholar
• Douglas SA, Dhanak D, Johns DG. From ‘gills to pills’: urotensin-II as a regulator of mammalian cardiorenal function. Trends Pharmacol Sci 2004;25:76–85
   PubMed Web of Science ®Google Scholar
• Iglewski M, Grant SR. Urotensin II-induced signaling involved in proliferation of vascular smooth muscle cells. Vasc Health Risk Manag 2010;6:723
   PubMedGoogle Scholar
• Hassan GS, Douglas SA, Ohlstein EH, Giaid A. Expression of urotensin-II in human coronary atherosclerosis. Peptides 2005;26:2464–72
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li Y, Wei R, et al. Urotensin II is an autocrine/paracrine growth factor for aortic adventitia of rat. Regul Pept 2008;151:88–94
   PubMed Web of Science ®Google Scholar
• Watanabe T, Suguro T, Kanome T, et al. Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages. Hypertension 2005;46:738–44
   PubMed Web of Science ®Google Scholar
• Mylona P, Cleland JG. Update of REACH-1 and MERIT-HF clinical trials in heart failure. Eur J Heart Fail 1999;1:197–200
   PubMed Web of Science ®Google Scholar
• Schiffrin EL. Role of endothelin-1 in hypertension and vascular disease. Am J Hypertens 2001;14:83S–9S
   PubMed Web of Science ®Google Scholar
• Barton M, Shaw S, Moreau P, Lüscher TF. Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in Vivo: role of ETA receptors for endothelin regulation. Biochem Biophys Res Commun 1997;238:861–5
   PubMed Web of Science ®Google Scholar
• Bruno RM, Sudano I, Ghiadoni L, et al. Interactions between sympathetic nervous system and endogenous endothelin in patients with essential hypertension. Hypertension 2011; 57:79–84
   PubMed Web of Science ®Google Scholar
• Nagaya N, Nishikimi T, Uematsu M, et al. Haemodynamic and hormonal effects of adrenomedullin in patients with pulmonary hypertension. Heart 2000;84:653–8
   PubMed Web of Science ®Google Scholar
• Nishida H, Horio T, Suzuki Y, et al. Plasma adrenomedullin as an independent predictor of future cardiovascular events in high-risk patients: comparison with C-reactive protein and adiponectin. Peptides 2008;29:599–605
   PubMed Web of Science ®Google Scholar
• Hu W, Zhou P-H, Zhang X-B, et al. Pathophysiological functions of adrenomedullin and natriuretic peptides in patients with primary aldosteronism. Endocrine 2015;48:661–8
   PubMed Web of Science ®Google Scholar
• Yang LL, Arab S, Liu P, et al. The role of endothelin-1 in myocarditis and inflammatory cardiomyopathy: old lessons and new insights. Can J Physiol Pharmacol 2005;83:47–62
   PubMed Web of Science ®Google Scholar
• Sharma, R, Coats, AJ, Anker, DS. The role of inflammatory mediators in chronic heart failure: cytokines, nitric oxide, and endothelin-1. Vol. 72. 2000, Shannon, Ireland: Elsevier
   Google Scholar
• Ishimitsu T, Ono H, Minami J, Matsuoka H. Pathophysiologic and therapeutic implications of adrenomedullin in cardiovascular disorders. Pharmacol Ther 2006;111:909–27
   PubMed Web of Science ®Google Scholar
• Kelly AS, Gonzalez-Campoy JM, Rudser KD, et al. Carvedilol–lisinopril combination therapy and endothelial function in obese individuals with hypertension. J Clin Hypertens 2012;14:85–91
   Web of Science ®Google Scholar
• Ames RS, Sarau HM, Chambers JK, et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999;401:282–6
   PubMed Web of Science ®Google Scholar
• Pandey A, Paliwal SK, Paliwal SK. Chemical feature-based molecular modeling of urotensin-II receptor antagonists: generation of predictive pharmacophore model for early drug discovery. J Chem 2014; 2014. http://www.hindawi.com.sci-hub.org/journals/jchem/2014/921863/
   Google Scholar
• Chalmers J, Macmahon S, Mancia G, et al. World Health Organization International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999;17:151–83
   PubMed Web of Science ®Google Scholar
• Zj J. The application of statistical analysis on medical science. Beijing, China: People's Medical Publishing House; 2008
   Google Scholar
• Gruson D, Ahn SA, Rousseau MF. Biomarkers of inflammation and cardiac remodeling: the quest of relevant companions for the risk stratification of heart failure patients is still ongoing. Biochem Med 2011;21:254–63
   Web of Science ®Google Scholar
• Maharjan P, Wu Y, He M, et al. Plasma urotensin II act as a diagnostic biomarker for acute coronary syndromes. Int J Pept Res Ther 2014;20:145–51
   Web of Science ®Google Scholar
• Djordjevic T, Belaiba RS, Bonello S, et al. Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arterioscler Thromb Vasc Biol 2005;25:519–25
   PubMed Web of Science ®Google Scholar
• Shi Xd LZ, Wu HC, Lv YH, et al. Effect of urotensin II on secretion of adrenomedullin fromhuman vascular endothelial cells. Chin J Cardiol 2005;33:836–9
   Google Scholar
• Matsushita M, Shichiri M, Imai T, et al. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens 2001;19:2185–90
   PubMed Web of Science ®Google Scholar
• Yu G, Yang T, Borlongan C, et al. Decreased plasma urotensin II levels inversely correlate with extent and severity of coronary artery disease. Am J Geriatr Cardiol 2007;4:105–10
   Google Scholar
• Gruson D, Rousseau M, Ahn S, et al. Circulating urotensin II levels in moderate to severe congestive heart failure: its relations with myocardial function and well established neurohormonal markers. Peptides 2006;27:1527–31
   PubMed Web of Science ®Google Scholar
• Patella V, Marino I, Arbustini E, et al. Stem cell factor in mast cells and increased mast cell density in idiopathic and ischemic cardiomyopathy. Circulation 1998;97:971–8
   PubMed Web of Science ®Google Scholar
• Johns D, Ao Z, Naselsky D, et al. Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. Naunyn–Schmiedeberg's Arch Pharmacol 2004;370:238–50
   Google Scholar
• Cheung BM, Leung R, Man YB, Wong LY. Plasma concentration of urotensin II is raised in hypertension. J Hypertens 2004;22:1341–4
   PubMed Web of Science ®Google Scholar
• Harwani SC, Chapleau MW, Legge KL, et al. Neurohormonal modulation of the innate immune system is proinflammatory in the prehypertensive spontaneously hypertensive rat, a genetic model of essential hypertension. Circ Res 2012;111:1190–7
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang B-H, Yu Y-R, et al. Adrenomedullin protects against fructose-induced insulin resistance and myocardial hypertrophy in rats. Peptides 2011;32:1415–21
   PubMed Web of Science ®Google Scholar
• Suguro T, Watanabe T, Ban Y, et al. Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension. Am J Hypertens 2007;20:211–7
   PubMed Web of Science ®Google Scholar